GPAT2 and acute myeloid leukemia: On the other hand, renal (55%), colorectal (47%), hepatocellular (64%), basal cell (67%) and hematological cancers (AML, 47%; UCSD CLL, 51%) showed a significantly higher percentage of samples with low expression of GPAT2 (p<0.01).